Results 131 to 140 of about 1,505,630 (287)

Recent advances in adoptive cell therapy for cancer immunotherapy

open access: yesFrontiers in Immunology
Adoptive cell therapy (ACT), a key direction in tumor immunotherapy, has achieved remarkable progress in recent years. This paper systematically reviews the current status and future trends of ACT, covering lymphokine-activated killer cells (LAK), tumor ...
Jiameng Qian   +3 more
doaj   +1 more source

A Drug‐Gated, Modular STAb‐T Immunotherapy With External Control

open access: yesAdvanced Science, EarlyView.
Engineered STAb‐TON cells act as programmable living factories that continuously secrete inactive antibody modules, which assemble extracellularly into a functional T cell engager only upon small‐molecule administration. This externally controlled platform enables reversible, on‐demand regulation of antitumor immunity, establishing a new paradigm for ...
Susana Luengo‐Arias   +23 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy

open access: yes, 2019
Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease.
Met, Özcan   +5 more
core   +1 more source

Selective Modulation of OTUB1 Noncanonical Function via a bioPhosTAC Strategy

open access: yesAdvanced Science, EarlyView.
This work positions the versatile performance of the peptide‐based bioPhosTAC platform for dissecting phosphorylation‐dependent biology and expanding the scope of induced‐proximity technologies. We demonstrated that selective manipulation of a tyrosine phosphorylation site is sufficient to propagate coordinated cellular consequences.
Seung Un Seo   +7 more
wiley   +1 more source

Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer‐Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A Transformer‐based AI framework, DLINP, screens millions of compounds to identify Co68, a cobalt‐pincer organometallic complex that biases TLR4‐MD2 signaling toward antitumor interferon activation while suppressing inflammatory toxicity through an early TLR4‐SYK‐STAT1 axis.
Xuefei Guo   +10 more
wiley   +1 more source

Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.

open access: yes, 2014
Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen ...
P Darcy (18763603)   +3 more
core  

Nicotinamide Metabolism Constrains Memory CD8+ T Cell Formation Through a Putative HS1BP3‐SIRT1‐FOXO3‐BCL6 Axis

open access: yesAdvanced Science, EarlyView.
ABSTRACT Memory T cells exhibit long‐term persistence, a defining feature that underpins durable clinical responses to adoptive immunotherapies. The mechanisms that integrate metabolic cues with transcriptional control of memory fate remain undetermined. Here, we identify HS1‐binding protein 3 (HS1BP3) is preferentially expressed in memory CD8+ T cells.
Siyang Wang   +13 more
wiley   +1 more source

SynNotch Receptors for Visualizing Immunoreceptor Force Transmission and Downstream Signaling In Vivo

open access: yesAdvanced Science, EarlyView.
A mechanically activated SynNotch reporter platform enables detection of force transmission through receptors as they mediate immune cell interactions. Targeting CD40 on B cells and TCR on T cells records force‐induced reporter activation across 2D coculture, 3D organoid, and implanted in mice, which also reveal force‐amplification of immune receptor ...
Menglan Li   +9 more
wiley   +1 more source

An Engineered HR1‐Stem Helix‐HR2 Trimeric Platform for Developing Broad‐Spectrum Coronavirus Vaccines

open access: yesAdvanced Science, EarlyView.
Sun et al. report a self‐assembling trimeric subunit vaccine platform termed RHS, which integrates the JN.1 receptor‐binding domain (RBD) with the heptad repeat 1 (HR1), stem helix (SH), and heptad repeat 2 (HR2) regions. The SARS‐CoV‐2 RHS vaccine elicits variant‐reactive RBD‐specific antibodies and cross‐reactive SH‐specific antibodies against ...
Xikui Sun   +18 more
wiley   +1 more source

CEA-Specific Next-Generation Chimeric Antigen Receptor-Engineered NK-92 Cells Effective in Colorectal Cancer Models

open access: yes
CEA-SPECIFIC NEXT-GENERATION CHIMERIC ANTIGEN RECEPTOR-ENGINEERED NK-92 CELLS EFFECTIVE IN COLORECTAL CANCER MODELS CEA-Specific Next-Generation Chimeric Antigen Receptor-Engineered NK-92 Cells Effective in Colorectal Cancer Models / Franzén, Alexander ...
Franzén, Alexander Sebastian
core  

Home - About - Disclaimer - Privacy